eFFECTOR Therapeutics, Inc. (EFTR): Price and Financial Metrics
EFTR Price/Volume Stats
| Current price | $1.69 | 52-week high | $37.00 |
| Prev. close | $1.78 | 52-week low | $1.66 |
| Day low | $1.66 | Volume | 130,855 |
| Day high | $1.80 | Avg. volume | 334,792 |
| 50-day MA | $10.27 | Dividend yield | N/A |
| 200-day MA | $13.51 | Market Cap | 6.23M |
EFTR Stock Price Chart Interactive Chart >
eFFECTOR Therapeutics, Inc. (EFTR) Company Bio
eFFECTOR Therapeutics, Inc., a biotechnology company, develops selective translation regulators for the treatment of cancer and other serious diseases. It focuses on small molecule drugs that act by selectively regulating translation that is known as protein synthesis. The company was incorporated in 2012 and is based in San Diego, California.
Latest EFTR News From Around the Web
Below are the latest news stories about EFFECTOR THERAPEUTICS INC that investors may wish to consider to help them evaluate EFTR as an investment opportunity.
eFFECTOR Therapeutics Announces New Positive Interim Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer PatientsMedian progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients Zotatifin generally well tolerated as dose escalation continues; Currently enrolling at 0.28 mg/kg in the ZF doublet evaluating zotatifin combined with fulvestrant and at 0.1 mg/kg in the ZFA triplet SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Dec. 08, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: |
eFFECTOR Receives U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast CancerDesignation is for 2nd or 3rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor Data updates and further development plans to be presented at 2023 San Antonio Breast Cancer Symposium (SABCS) SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, toda |
eFFECTOR to Present New Clinical Data from Dose Escalation and Phase 2 Expansion Cohorts of Zotatifin in Patients with ER+ Metastatic Breast Cancer at SABCS 2023 Annual MeetingSOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced a poster presentation of new clinical data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 clinical study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer (mBC) at the San Antonio Breast Canc |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayPre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning! |
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateManagement intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium (SABCS) Topline results from Phase 2b KICKSTART trial in non-small cell lung cancer (NSCLC) now anticipated in first quarter of 2024 Collaboration initiated with Northwestern University on investigator-initiated Phase 1 dose escalation trial with tomivosertib in patients with Acute Myeloid Leukemia |
EFTR Price Returns
| 1-mo | -86.85% |
| 3-mo | -84.09% |
| 6-mo | -87.93% |
| 1-year | -83.06% |
| 3-year | -99.31% |
| 5-year | N/A |
| YTD | -85.54% |
| 2023 | 9.31% |
| 2022 | -94.84% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...